BIOA News

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

BioAge Labs to Present at Upcoming Investor Conferences

Number of shares and votes in BioArctic AB (publ) as of August 31, 2026

Form 8-K

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioAge Labs administra la primera dosis a un participante en el ensayo de fase 2 de BGE-102

BioAge Labs, partenaire de HitGen, a administré la première dose à un participant dans le cadre de l'essai de phase 2 du BGE-102, un nouvel inhibiteur oral de NLRP3 destiné à réduire les risques cardiovasculaires

BioAge Labs, Partner von HitGen, verabreicht erste Dosis an Teilnehmer der Phase-2-Studie zu BGE-102, einem neuartigen oralen NLRP3-Inhibitor zur Senkung des kardiovaskulären Risikos